EMA Authorised: Leqembi (Lecanemab) — Eisai GmbH

View source ↗

Summary

The EMA has authorised Leqembi (lecanemab) for cognitive dysfunction and Alzheimer's disease, with Eisai GmbH as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Dysfunction

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

Status: Authorised. Therapeutic area: Cognitive Dysfunction;Alzheimer Disease. MAH: Eisai GmbH. Decision date: 11/06/2026